Flortaucipir f-18
Looking up MedlinePlus…
From MedlinePlus, U.S. National Library of Medicine
Dosing in kidney impairment
| a Assumed radiation weighting factor, wr, (formerly defined as quality factor, Q) of 1 for conversion of absorbed dose (Gray or rads) to dose equivalent (Sieverts or rem) for F 18. To obtain radiation absorbed dose in rad/mCi from above table, multiply the dose in μGy/MBq by 0.0037 (e.g., 14 μGy/MBq x 0.0037 = 0.0518 rad/mCi). | |
| Organ/Tissue | Mean Absorbed Dose Per Unit Administered Activity (μGy/MBq) |
| Adrenal glands | 14 |
| Brain | 8 |
| Breasts | 7 |
| Gallbladder wall | 38 |
| Lower large intestine wall | 35 |
| Small intestine wall | 85 |
| Stomach wall | 13 |
| Upper large intestine wall | 96 |
| Heart wall | 30 |
| Kidneys | 40 |
| Liver | 57 |
| Lungs | 34 |
| Muscle | 9 |
| Ovaries | 21 |
| Pancreas | 14 |
| Red bone marrow | 10 |
| Osteogenic cells | 12 |
| Skin | 6 |
| Spleen | 10 |
| Testes | 7 |
| Thymus gland | 9 |
| Thyroid | 7 |
| Urinary bladder wall | 38 |
| Uterus | 18 |
| Total body | 12 |
| Effective dose (μSv/MBq)a | 24 |
Preparation and administration
Prepare this dose
Your numbers for flortaucipir f-18. Take vial strength, diluent, and limits from the label below.
Enter a dose to see draw volume, final concentration, and rates.
Recommended Dosage and Administration Instructions Recommended Dose The recommended amount of radioactivity to be administered for PET imaging is 370 MBq (10 mCi), administered as an intravenous bolus injection in a total volume of 10 mL or less. Preparation and Administration Assessment of pregnancy status is recommended in females of reproductive potential before administering TAUVID.
Use aseptic technique and radiation shielding during the preparation and administration of TAUVID [see Dosage and Administration] . Visually inspect the radiopharmaceutical solution prior to administration. Do not use it if it contains particulate matter or if it is discolored (TAUVID is a clear, colorless solution). TAUVID may be diluted aseptically with 0.9% Sodium Chloride Injection to a maximum dilution of 1:5 by the end-user.
Diluted product should be used within 4 hours of dilution and prior to product expiry. Assay the dose in a suitable dose calibrator prior to administration. Post-Administration Instructions Follow the TAUVID injection with an intravenous flush of 0.9% Sodium Chloride injection, USP. Dispose of any unused TAUVID in compliance with applicable regulations.
Preparation for Image Interpretation Before interpreting the image, review the brain to determine the lobar anatomy. Interpret the images by first evaluating the temporal lobes, followed by occipital, parietal, and frontal lobes bilaterally. To evaluate the temporal lobes, subdivide them into four quadrants by placing the horizontal crosshair immediately posterior to the brainstem nuclei and then scrolling inferiorly to place the vertical crosshair through the widest portion of the temporal pole, thus obtaining the anterolateral temporal (ALT), anterior mesial temporal (AMT), posterolateral temporal (PLT) and posterior mesial temporal (PMT) quadrants.
See Figure 2 for an example (the left and right image panels show the same scan in two different color scales). Figure 2: Temporal Lobe Quadrants Figure 2
Contraindications
None. None. ( 4 )
Pregnancy and lactation
Pregnancy
8.1 Pregnancy Risk Summary All radiopharmaceuticals, including TAUVID, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation doses with administration of TAUVID. TAUVID is not likely to be used in females of reproductive age. There are no available data on TAUVID use in pregnant women. No animal reproduction studies using flortaucipir F 18 have been conducted to evaluate its effect on female reproduction and embryo-fetal development. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
For breastfeeding, also see LactMed (National Library of Medicine), which summarizes milk levels and infant effects.
Supply and cost
Drug shortage status
Recalls (last 24 months)
Therapeutic equivalence (Orange Book)
Price ladder
Not the price at the counterThese are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.